Targeting Cancer Cell Migration with Pentamethinium Salts

PETRLÁKOVÁ, Kateřina; Jiří NAVRÁTIL; Milan JAKUBEK a Michal MASAŘÍK. Targeting Cancer Cell Migration with Pentamethinium Salts. In EACR Innovative Cancer Science: Annual Congress of the European Association of Cancer Research. 2023.

Základní údaje

Originální název

Targeting Cancer Cell Migration with Pentamethinium Salts

Autoři

PETRLÁKOVÁ, Kateřina ORCID; Jiří NAVRÁTIL ORCID; Milan JAKUBEK a Michal MASAŘÍK

Vydání

EACR Innovative Cancer Science: Annual Congress of the European Association of Cancer Research, 2023

---

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ne

Organizační jednotka

Lékařská fakulta

---

Anotace

V originále

Tumor invasiveness and metastasis cause over 90 % of cancer-related deaths, yet no effective drugs specifically targeting these processes exist. While cytostatic therapies inhibit tumor growth, migrastatic agents aim to prevent cancer cell movement and metastasis. A combination of both strategies could enhance treatment outcomes. This study explores pentamethinium salts (PMS), a class of fluorescent compounds with varying cytotoxicity that influence tumor cell migration. Some PMS derivatives selectively bind to cardiolipin in mitochondria, offering high fluorescence stability and minimal phototoxicity. We show that PMS inhibits DHODH-dependent respiration, a key step in pyrimidine synthesis, and suppresses oxidative phosphorylation (OXPHOS) and ATP production. Our findings highlight BCV 141’s interaction with mitochondrial structures, its binding to DHODH and the IL-6 receptor, and its potential to reduce lung metastases in mice.